ABCG2 p.Ser187Thr
Predicted by SNAP2: | A: D (66%), C: D (71%), D: D (80%), E: D (80%), F: D (85%), G: D (75%), H: D (80%), I: D (85%), K: D (85%), L: D (80%), M: D (80%), N: D (66%), P: D (85%), Q: D (75%), R: D (85%), T: D (63%), V: D (75%), W: D (85%), Y: D (80%), |
Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, R: D, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Functional characterization of human breast cancer... Mol Pharmacol. 2003 Dec;64(6):1452-62. Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD
Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.
Mol Pharmacol. 2003 Dec;64(6):1452-62., [PMID:14645676]
Abstract [show]
To evaluate the function and substrate specificity of human breast cancer resistance protein (BCRP, ABCG2) in the absence of cofactors or heterologous partner proteins, Xenopus laevis oocytes were injected with cRNA of wild-type or mutant (R482T) BCRP. High expression of BCRP was observed on the oocyte surface. Accumulation and efflux assays revealed that oocytes expressing R482T transported daunorubicin (DNR), mitoxantrone (MX), rhodamine 123, and flavopiridol (FLV), whereas wild-type BCRP transported only MX and FLV, in agreement with observations in mammalian and other systems. Transport activity was completely inhibited by fumitremorgin C, a known inhibitor of BCRP. Injection of oocytes with cRNA containing mutations of serine 187 in the ATP-binding cassette signature motif (S187T or S187A) resulted in strong expression of the mutant forms; however, these oocytes were devoid of transporter activity. When oocytes were coinjected with R482T and R482T/S187T, DNR transport was inhibited in a manner dependent on the amount of R482T/S187T cRNA added, consistent with the idea that the active form of BCRP is a homodimer or homomultimer. Substrate interaction studies found that no two substrates reciprocally inhibited the efflux of the other. Although FLV proved to be an effective inhibitor of both MX and DNR transport, and MX inhibited DNR transport, the other substrates tested had only weak or no inhibitory activity, indicating a complex nature of substrate interaction with the BCRP homodimer. We conclude that the X. laevis oocyte heterologous expression system is a valid and effective means of studying BCRP function and substrate specificity.
Comments [show]
None has been submitted yet.
No. Sentence Comment
4 Injection of oocytes with cRNA containing mutations of serine 187 in the ATP-binding cassette signature motif (S187T or S187A) resulted in strong expression of the mutant forms; however, these oocytes were devoid of transporter activity.
X
ABCG2 p.Ser187Thr 14645676:4:111
status: VERIFIED5 When oocytes were coinjected with R482T and R482T/S187T, DNR transport was inhibited in a manner dependent on the amount of R482T/S187T cRNA added, consistent with the idea that the active form of BCRP is a homodimer or homomultimer.
X
ABCG2 p.Ser187Thr 14645676:5:50
status: VERIFIEDX
ABCG2 p.Ser187Thr 14645676:5:130
status: VERIFIED57 The PCR product was ligated into the pCR Blunt TOPO II TABLE 1 Summary of cDNA constructs made as templates for producing BCRP cRNA Construct Plasmid Features of the BCRP cRNA Produced RNA Polymerase Consensus Sequence Upstream from BCRP cDNA I pSP64poly(A) R482T-poly(A) SP6 II pCR Blunt TOPO II Kozak-R482T-poly(A) T7 III pSD64TR 5ЈUTR-Kozak-R482T-3ЈUTR-poly(A) other BCRP forms: 5ЈUTR-Kozak-R482-3ЈUTR-poly(A) 5ЈUTR-Kozak-R482T/S187T- 3ЈUTR-poly(A) 5ЈUTR-Kozak-R482T/ S187A-3ЈUTR-poly(A) SP6 III- pSD64TR 5ЈUTR-R482T-3ЈUTR-poly(A) SP6 5ЈUTR, 3ЈUTR, portions of the 5Ј- and 3Ј-UTR of the Xenopus laevis beta-globin gene; Kozak, modified sequences proximate to the start codon, as described under Materials and Methods; Poly(A), addition of a poly(A) tail, as described under Materials and Methods.
X
ABCG2 p.Ser187Thr 14645676:57:461
status: VERIFIED60 Introduction of S187T and S187A Mutations into Human BCRP cDNA.
X
ABCG2 p.Ser187Thr 14645676:60:16
status: VERIFIED64 The S187T primer pair was 5Ј-G TTT ATC CGT GGT GTG AC T GGA GGA GAA AG-3Ј and 5Ј-CT TTC TCC TCC AGT CAC ACC ACG GAT AAA C-3Ј, and the S187A primer pair was 5Ј-G TTT ATC CGT GGT GTG GC T GGA GGA GAA AG-3Ј and 5Ј-CT TTC TCC TCC AGC CAC ACC ACG GAT AAA C-3Ј.
X
ABCG2 p.Ser187Thr 14645676:64:4
status: VERIFIED163 To determine whether dimerization is required for BCRP activity, a mutant construct was created by substituting the highly conserved serine at residue 187 in the ABC signature motif with threonine (R482T/S187T) or alanine (R482T/S187A).
X
ABCG2 p.Ser187Thr 14645676:163:204
status: VERIFIED181 Indeed, when BCRP (R482T) was coinjected with varying amounts of the "dominant-negative" construct S187T/R482T, the transport of DNR was significantly inhibited in a manner dependent on the amount of the S187T mutant construct added (Fig. 5C), strongly suggesting that homodimerization or multimerization is essential for BCRP activity.
X
ABCG2 p.Ser187Thr 14645676:181:99
status: VERIFIEDX
ABCG2 p.Ser187Thr 14645676:181:204
status: VERIFIED182 The degree of inhibition seemed to plateau after the addition of 48 ng of the "dominant-negative" construct; for technical reasons, we were unable to inject the oocytes with amounts of S187T mutant cRNA in excess of 72 ng.
X
ABCG2 p.Ser187Thr 14645676:182:185
status: VERIFIED199 Expression of dominant-negative construct was confirmed by Western blot (A) and by DNR accumulation (25 M, B) in control or R482T-expressing oocytes (f), R482T/S187T- expressing oocytes (o), or R482T/S187A-expressing oocytes (gray o).
X
ABCG2 p.Ser187Thr 14645676:199:168
status: VERIFIED201 DNR accumulation (25 M, C) was determined in oocytes coinjected with 24 ng of R482T cRNA and different amounts (0 to 72 ng) of the R482T/S187T construct cRNA (f).
X
ABCG2 p.Ser187Thr 14645676:201:145
status: VERIFIED202 As control, the accumulation of 25 M DNR was also determined in control (Ⅺ) or oocytes injected with 24 ng of R482T/S187T cRNA only (o).
X
ABCG2 p.Ser187Thr 14645676:202:131
status: VERIFIED233 Hence, we made two mutations of serine 187 in this signature motif of BCRP R482T, one to an amino acid that, like serine, has a polar side chain (threonine, S187T) and the other to a nonpolar side chain amino acid (alanine, S187A).
X
ABCG2 p.Ser187Thr 14645676:233:157
status: VERIFIED239 When the S187T mutation was coexpressed with BCRP R482T in the oocytes, the S187T mutant protein acted as would a dominant-negative inhibitor of BCRP transport of DNR, with the degree of inhibition increasing in proportion to the amount of S187T cRNA injected.
X
ABCG2 p.Ser187Thr 14645676:239:9
status: VERIFIEDX
ABCG2 p.Ser187Thr 14645676:239:76
status: VERIFIEDX
ABCG2 p.Ser187Thr 14645676:239:240
status: VERIFIED241 Although it is possible that the inhibition caused by the S187A/T mutants was the result of the mutant saturating a limiting and essential oocyte cellular component crucial for protein transport or maturation, it is more likely that the inhibition was analogous to a "dominant-negative" effect of the S187T mutant.
X
ABCG2 p.Ser187Thr 14645676:241:301
status: VERIFIED245 This may have occurred because the affinity of A-to-A and I-to-I homodimeric partners may be greater than that of the S187T mutant-to-active BCRP heterodimeric partners.
X
ABCG2 p.Ser187Thr 14645676:245:118
status: VERIFIED247 Because of injection volume constraints and the viscosity of highly concentrated cRNA solutions, we were technically unable to inject the oocytes with amounts of the S187T mutant form in excess of 72 ng.
X
ABCG2 p.Ser187Thr 14645676:247:166
status: VERIFIED[hide] Identification of a urate transporter, ABCG2, with... Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10338-42. Epub 2009 Jun 8. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M
Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10338-42. Epub 2009 Jun 8., 2009-06-23 [PMID:19506252]
Abstract [show]
Genome-wide association studies (GWAS) have successfully identified common single nucleotide polymorphisms (SNPs) associated with a wide variety of complex diseases, but do not address gene function or establish causality of disease-associated SNPs. We recently used GWAS to identify SNPs in a genomic region on chromosome 4 that associate with serum urate levels and gout, a consequence of elevated urate levels. Here we show using functional assays that human ATP-binding cassette, subfamily G, 2 (ABCG2), encoded by the ABCG2 gene contained in this region, is a hitherto unknown urate efflux transporter. We further show that native ABCG2 is located in the brush border membrane of kidney proximal tubule cells, where it mediates renal urate secretion. Introduction of the mutation Q141K encoded by the common SNP rs2231142 by site-directed mutagenesis resulted in 53% reduced urate transport rates compared to wild-type ABCG2 (P < 0.001). Data from a population-based study of 14,783 individuals support rs2231142 as the causal variant in the region and show highly significant associations with urate levels [whites: P = 10(-30), minor allele frequency (MAF) 0.11; blacks P = 10(-4), MAF 0.03] and gout (adjusted odds ratio 1.68 per risk allele, both races). Our data indicate that at least 10% of all gout cases in whites are attributable to this causal variant. With approximately 3 million US individuals suffering from often insufficiently treated gout, ABCG2 represents an attractive drug target. Our study completes the chain of evidence from association to causation and supports the common disease-common variant hypothesis in the etiology of gout.
Comments [show]
None has been submitted yet.
No. Sentence Comment
69 The physiological importance of ABCG2 in humans is illustrated by 0.0 0.5 1.0 1.5 noitalumuccAetarU nim021/etycoo/lomp H2O WT WT +FTC S187T 0 100 200 300 400 0 2 4 noitalumuccAetarU nim06/etycoo/lomp Urate Concentration ( µM) 0 2 4 6 8 10 0.00 0.05 0.10 nim/etycoo/lomp:xulffE Internal oocyte concentration (µM) 0 20 40 60 0.4 0.6 0.8 1.0 gniniameretarUevitaleR * 0.0 0.5 1.0 1.5 noitalumuccAetarU nim021/etycoo/lomp H2O MRP4ABCG2 ** A B C D E ** ** 500 ** ** ** ** * ** ** ** G F Time (min) 0.0 0.5 1.0 1.5 2.0 eAccumulationtarUevitaleR ** LLCPK : control +FTC basal brush border membrane Fig. 1.
X
ABCG2 p.Ser187Thr 19506252:69:134
status: NEW72 (B) Urate accumulation in oocytes injected with H2O, ABCG2 WT mRNA (incubated with or without 5 M FTC), or the nonfunctional ABCG2 mutant S187T (N ϭ 10 samples each and n ϭ 20 oocytes each for all accumulation experiments).
X
ABCG2 p.Ser187Thr 19506252:72:146
status: NEW73 (C) Urate accumulation is dependent on the extracellular urate concentration (H2O [blue circles]; S187T [black squares]; WT [red triangles]; N ϭ 10 and n ϭ 20 each).
X
ABCG2 p.Ser187Thr 19506252:73:98
status: NEW